Oral Abstract Session:
269. Flu and other Vaccines in Children
Saturday, October 6, 2018: 2:00 PM-3:15 PM
Room: W 2002

Tracks: Adult ID, Epidemiology and Infection Control, HIV-STD-TB, Investigative ID, Pediatric ID, Trainee

Moderators:  Angela P. Campbell, MD, MPH, FPIDS, FIDSA, Centers for Disease Control and Prevention and Janet Englund, MD, FIDSA, Seattle Children's Hospital

2:00 PM
Individual Patient-Level Data Meta-Analysis of Live Attenuated and Inactivated Influenza Vaccine Effectiveness among US Children, 2013-14 through 2015-16
Jessie Chung, MPH; Brendan Flannery, PhD; Rodolfo Begue, MD; Herve Caspard, MD, ScD; Laurie Demarcus, MPH; Ashley Fowlkes, MPH; Geeta Kersellius, MPH, MBA; Andrea Steffens, MPH; Alicia M. Fry, MD, MPH
2:15 PM
Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
Sybil Tasker, MD, MPH, FIDSA; Vyjayanthi Krishnan, PhD; Stephan Bart, MD; Anvar Suyundikov, PhD; Peta-Gay Booth, MD; Anna Wight O'Rourke, MS; Jianfeng Zhang, PhD; Bertrand Georges, PhD; Scot Roberts, PhD
2:30 PM
Predicting risk of breakthrough invasive pneumococcal disease in children after 13-valent pneumococcal conjugate vaccination
Melike Yildirim, MS; Stephen I. Pelton, MD; Pinar Keskinocak, PhD; Inci Yildirim, MD PhD MSc
2:45 PM
Retrospective Evaluation of Mismatch from Egg-based Isolation of Influenza Strains Compared to Cell-based Isolation and the Possible Implications for Vaccine Effectiveness
S Rajaram, MD, MRCPCH, MFPM, MBA; Josephine Van Boxmeer, MPhil; Brett Leav, MD; Pirada Suphaphiphat, PhD; Ike Iheanacho, MBBS, BSc; Kristin Kistler, PhD
3:00 PM
A Model to Estimate the Potential Impact of Immunizations on Respiratory Syncytial Virus (RSV) Disease Burden among Infants in the United States
Gayle E. Langley, MD, MPH; Alexandra Wheatley, BS; Bishwa Adhikari, PhD; Martin I. Meltzer, PhD; Gabriel Rainisch, MPH

CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.